HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis.

Abstract
Olopatadine hydrochloride nasal spray 0.6% (OLO) and azelastine nasal spray 137 micrograms (AZE) are effective in treating allergic rhinitis and AZE is indicated for nonallergic vasomotor rhinitis (VMR). This study evaluates the relative safety and efficacy of OLO and AZE in patients with VMR. This randomized, double-blind, parallel-group, multicenter study compared OLO (an investigational use) with AZE over 14 days in patients (n = 129) ≥12 years of age with chronic VMR. Efficacy included the severity of nasal symptom scores. Safety included adverse events (AEs) and nasal examinations. Patient perceptions of treatment satisfaction and changes in allergy condition were determined using the Treatment Satisfaction Questionnaire for Medication and Patient Global Assessment scores. In the OLO and AZE groups, reflective scores for individual nasal symptoms (nasal congestion, rhinorrhea, postnasal drip, and sneezing) and total nasal VMR symptom scores decreased significantly from baseline to day 14 (p < 0.05). No significant between-group differences were observed (p > 0.05). No serious AEs were reported in either group. Overall, 22 and 20 AEs were reported in the OLO and AZE groups, respectively. The most common AE was taste disturbance, reported by three (5.3%) and six (10.3%) patients in the OLO and AZE groups, respectively. Patients in both groups reported similar treatment satisfaction scores and a majority of patients in both groups perceived an overall improvement in their rhinitis condition. OLO has a similar efficacy and safety profile to AZE for the management of VMR in patients ≥12 years of age.
AuthorsPhil Lieberman, Eli O Meltzer, Craig F LaForce, Amy L Darter, Maria J Tort
JournalAllergy and asthma proceedings (Allergy Asthma Proc) 2011 Mar-Apr Vol. 32 Issue 2 Pg. 151-8 ISSN: 1539-6304 [Electronic] United States
PMID21352639 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Allergic Agents
  • Dibenzoxepins
  • Nasal Sprays
  • Phthalazines
  • Olopatadine Hydrochloride
  • azelastine
Topics
  • Administration, Intranasal
  • Adult
  • Aged
  • Anti-Allergic Agents (therapeutic use)
  • Dibenzoxepins (therapeutic use)
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nasal Mucosa (drug effects)
  • Nasal Sprays
  • Olopatadine Hydrochloride
  • Phthalazines (therapeutic use)
  • Rhinitis, Vasomotor (drug therapy)
  • Taste
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: